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ABSTRACT Hemextin AB complex from the venom of Hemachatus haemachatus is the ﬁrst known natural anticoagulant that
speciﬁcally inhibits the enzymatic activity of blood coagulation factor VIIa in the absence of factor Xa. It is also the only known
heterotetrameric complex of two three-ﬁnger toxins. Individually only hemextin A has mild anticoagulant activity, whereas hemextin
B is inactive. However, hemextin B synergistically enhances the anticoagulant activity of hemextin A and their complex exhibits
potent anticoagulant activity. In this study we characterized the nature of molecular interactions leading to the complex formation.
Circular dichroism studies indicate the stabilization of b-sheet in the complex. Hemextin AB complex has an increased apparent
molecular diameter in both gas and liquid phase techniques. The complex formation is enthalpically favorable and entropically
unfavorable with a negative change in the heat capacity. Thus, the anticoagulant complex shows less structural ﬂexibility than
individual subunits. Both electrostatic and hydrophobic interactions are important for the complexation; the former driving the
process and the latter helping in the stabilization of the tetramer. The tetramer dissociates into dimers and monomers with the
increase in the ionic strength of the solution and also with increase in the glycerol concentration in the buffer. The two dimers formed
under each of these conditions display distinct differences in their apparent molecular diameters and anticoagulant properties.
Based on these results, we have proposed a model for this unique anticoagulant complex.

INTRODUCTION
Blood coagulation is a physiological response to vascular
injury that results in the formation of hemostatic plug, which
prevents blood loss (1,2). The process is initiated by tissue
factor (TF), a cellular receptor for the activated coagulation
factor VIIa (FVIIa), which is exposed after vascular injury (3).
FVIIa bound to TF activates factor X (FX) and factor IX.
Activated factor X (FXa) converts small amounts of prothrombin to thrombin (4). Thrombin in turn ampliﬁes the
coagulation cascade by activating the platelets (5) and factors
(6) and VIII (7,8). Coagulation is propagated when factor IXa
binds to factor VIIIa to form intrinsic tenase, a complex that
efﬁciently activates FX. FXa then binds to factor Va to form
prothrombinase, thereby increasing the rate of FXa-mediated
conversion of prothrombin to thrombin by .300,000-fold
(9). The resultant burst of thrombin rapidly converts ﬁbrinogen to ﬁbrin. Fibrin monomers polymerize to form the ﬁbrin
mesh that is stabilized and cross-linked by transglutaminase
factor XIIIa (10,11). Thus the initial formation of TF-FVIIa
complex is crucial for the clot initiation and is considered an
ideal target for the treatment of thromboembolic disorders.
Drugs that target this complex are potent inhibitors of coagulation and thus are highly sought after. Though, naturally
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occurring inhibitors of FVIIa have been identiﬁed, they are
not speciﬁc. For example, dysinosin A isolated from the sponge
family Dysideidae inhibits FVIIa with a Ki of 108 nM. However, it also an inhibitor of thrombin (12,13). Until recently
only two natural anticoagulants targeting speciﬁcally the TFFVIIa complex has been identiﬁed. They are tissue factor
pathway inhibitor (TFPI) (14,15) and nematode anticoagulant
peptide (NAPc2) (16,17). TFPI is a 42-kDa plasma glycoprotein consisting of three tandem Kunitz-type domains. The
ﬁrst and second domains inhibit TF-FVIIa and FXa, respectively. The third Kunitz domain and the C-terminal basic region
of the molecule have heparin-binding sites. The anticoagulant
action of TFPI is a two-stage process. The second Kunitz
domain binds ﬁrst to a molecule of FXa and deactivates it. The
ﬁrst domain then rapidly binds to an adjacent TF-FVIIa
complex, preventing further activation of FX (18–20). On the
other hand, NAPc2 is an 8-kDa short polypeptide. It ﬁrst binds
to FXa or zymogen FX to form a binary complex before its
interaction and inhibition of membrane-bound TF-FVIIa (21).
Therefore, despite the structural differences, both inhibitors
form a quaternary complex with TF-FVIIa-FXa. Further,
in both the complexes the active site of FVIIa is occupied by
the respective inhibitors and is not accessible.
Snake venoms are veritable gold mines of anticoagulant
proteins (22,23). Recently, we isolated and characterized a
novel anticoagulant protein complex (hemextin AB complex)
from the venom of elapid snake Hemachatus haemachatus
(African ringhals cobra) (24,25). Hemextin AB complex
doi: 10.1529/biophysj.106.100164
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speciﬁcally and noncompetitively inhibits the TF-FVIIa
complex with a Ki of 25 nM. Further, it inhibits FVIIa in the
absence of TF and FX. Thus, unlike TFPI and NAPc2, this
unique complex neither requires FX scaffold nor does it bind
to the active site of FVIIa (24).
Structurally, hemextin AB complex consists of two
proteins—hemextin A and hemextin B, both of which belong to the three-ﬁnger toxin family of snake venom proteins.
Individually, only hemextin A exhibits a mild anticoagulant
activity, whereas hemextin B is inactive. However, hemextin
B synergistically enhances the anticoagulant activity of
hemextin A and their complex has potent anticoagulant activity. Thus, the formation of this unique synergistic complex
of three-ﬁnger toxins is important for its ability to inhibit clot
initiation (24). There are only a few noncovalent protein complexes in snake venoms that do not contain phospholipase A2
as an integral part, such as rhodocetin (26,27) and pseutarin
C (28,29). Hemextin AB complex is the only known snake
venom protein complex formed by the interaction between
two three-ﬁnger toxins and is the only known heterotetrameric complex of three-ﬁnger toxins.
Since hemextin AB complex is both structurally and functionally unique, we have investigated the molecular interactions involved in the formation of this novel complex. In
particular we have examined the role of electrostatic and hydrophobic interactions in the formation of tetrameric anticoagulant complex. Hemextin AB complex has identical molecular
diameter in both gas and solution phases. Isothermal titration
calorimetry (ITC) studies reveal that the complex formation
is entropically unfavored, which indicates the reduced structural ﬂexibility of the complex. Hemextin AB assembly is an
enthalpically driven process with some conformational changes
accompanying the complexation. The tetrameric complex behaves differently in buffers of higher ionic strength. It is also
sensitive to the presence of glycerol in the buffer solution.
Thus, a complex interplay of electrostatic and hydrophobic
interactions drives the formation and stabilization of this
novel anticoagulant protein complex. Based on our observations, we propose a model for the assembly of hemextin
AB complex.
MATERIALS AND METHODS
Puriﬁcation of hemextins A and B
Hemextin A and hemextin B were puriﬁed using the methods described
earlier (24). Brieﬂy, H. haemachatus crude venom (100 mg in 1 ml distilled
water) was applied to a Superdex 30 gel ﬁltration column (1.6 3 60 cm)
equilibrated with 50 mM Tris-HCl buffer (pH 7.4) and eluted using the same
buffer, using an ÄKTA Puriﬁer system (Amersham Biosciences, Uppsala,
Sweden). Fractions containing potent anticoagulant activity were pooled and
subfractionated on a Uno S-6 (Bio-Rad, Hercules, CA; column volume, 6 ml)
cation-exchange column. The peaks containing hemextin A and hemextin B
were further puriﬁed using reversed-phase high-performance liquid chromatography (RP-HPLC) on a Jupiter C18 (1 3 25 cm) column. Both
proteins were found to be homogeneous with molecular masses of 6835.00
6 0.52 and 6792.56 6 0.32 Da, respectively, as determined by electrospray
ionization mass spectrometry (ESI-MS) (24).
Biophysical Journal 93(11) 3963–3976
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Circular dichroism spectroscopic studies
Far-ultraviolet (UV) circular dichroism (CD) spectra (260–190 nm) were
recorded using a Jasco J-810 spectropolarimeter (Jasco, Tokyo, Japan). All
measurements were carried out at room temperature (25°C) using 0.1 cm
pathlength stoppered cuvettes. The instrument optics was ﬂushed with 30 l/min
of nitrogen gas. The spectra were recorded using a scan speed of 50 nm/min,
resolution 0.2 nm, and bandwidth 2 nm. For each spectrum, a total of six
scans were recorded, averaged, and baseline subtracted. The conformation
of hemextin A and hemextin B at different concentrations were monitored in
50 mM Tris-HCl buffer (pH 7.4). To study the complex formation, titration
experiments were carried out by keeping the concentration of hemextin A
constant at 0.5 mM, and varying the concentration of hemextin B.

Determination of molecular diameters
The apparent molecular diameters of the hemextin AB complex and the
individual hemextins were determined in both the gas and solution phases
using Gas Phase Electrophoretic Mobility Macromolecule Analyzer (GEMMA)
and dynamic light scattering (DLS), respectively.

GEMMA
The molecular diameters in the gas phase were determined with GEMMA
(30) using a nano-differential mobility analyzer, model 3980, with a standard
condensation particle counter, type 3025 (TSI, St Paul, MN). The instrument
was operated in the ‘‘cone jet’’ mode with an operating voltage between 2.5
and 3.0 kV, resulting in currents from 200 to 300 nA. Filtered ambient air at
2 l/min and a concentric sheath gas ﬂow of ﬁltered CO2 at 0.1 l/min was used
to stabilize the electrospray against corona discharge. Sample solutions of
hemextin A (4 ng/ml) and hemextin B (4 ng/ml) were prepared in 20 mM
ammonium acetate (pH 7.4) immediately before the experiment. Hemextin
AB complex (4.5 ng/ml) was reconstituted in the above buffer and was incubated at 37°C for 10 min. Another three-ﬁnger protein, toxin C, isolated
and puriﬁed from the same venom, was used as a control in the GEMMA
experiments. The samples were infused into the electrospray chamber with
an inlet ﬂow rate of 100 nl/min. Twenty scans over the whole electrophoretic
mobility (EM) diameter range (0–25 nm) were recorded and averaged to obtain a GEMMA spectrum. Data presentation was done without the application of any smoothing algorithm.

DLS
The complex formation studies with DLS were carried out at 25°C using a
BI200SM instrument (Brookhaven Instruments, Holstville, NY). A vertically polarized argon ion laser (514.2 nm, 75 mW; NEC model GLG-3112)
was used as the light source. Sample solutions of hemextin A (4 mM),
hemextin B (4.1 mM), and hemextin AB complex (4.6 mM) in 50 mM TrisHCl buffer (pH 7.4) were prepared immediately before the experiment. The
hydrodynamic diameter for the hemextin AB complex and the individual
hemextins were recorded at 25°C in solutions of different ionic strengths and
at different glycerol concentrations. The ionic strengths were varied by the
addition of NaCl. From the measured translational diffusion coefﬁcient (DT),
the hydrodynamic radius (RH) can be calculated using the Stokes-Einstein
relation:

DT ¼ kB T=6phRH ;

(1)

where, kB is the Boltzmann constant, T is the temperature in Kelvin, and h is
the viscosity of the solvent. The intensity-intensity time correlation functions
were obtained with a BI-9000 digital correlator. The particle size and size
distribution were obtained by analyzing the ﬁeld correlation function jg(1)(t)j
using constrained regularized CONTIN method (31).
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Thermodynamics of hemextin AB
complex formation
ITC experiments were performed using a Microcal VP-ITC calorimeter
(Microcal LLC, Northampton, MA) to study the thermodynamics of the formation of hemextin AB complex. Unless otherwise noted, all experiments were
performed in 50 mM Tris-HCl buffer (pH 7.4). Both the proteins were dissolved in the same buffers, ﬁltered and degassed before titration. Hemextin
A (0.1 mM) was kept in the sample cell and hemextin B (1 mM) was loaded
into the syringe. The syringe stirring speed was set to 300 rpm. Data were
collected in high feedback mode, with a ﬁlter period of 3 s. For each experiment, a control titration was performed by injecting hemextin B into the
appropriate buffer. Finally, the control data were subtracted from the raw
data to obtain an isotherm corrected for heats of dilution. The ﬁrst injections
presented defects in the baseline and these data points were not included
in the ﬁtting process. The calorimetric data were processed and ﬁtted to
the single set of identical sites model using Microcal Origin (Version 7.0)
data analysis software supplied with the instrument. The expression for the
heat released per injection, DQ(i), is given by

DQðiÞ ¼ QðiÞ 1 dVi = 2V0 ½QðiÞ 1 Qði  1Þ  Qði  1Þ; (2)
where Q(i) is the total heat content, dVi is the volume injected at the ith
injection, and V0 is the cell volume. The total heat content Q of the solution
(determined relative to zero for the unliganded species) contained in the active
cell volume, V0, was calculated according to Eq. 3, where KA is the binding
afﬁnity constant, n is the number of sites, DH is the enthalpy of ligand binding,
and Mt and Xt are the bulk concentration of macromolecule and ligand,
respectively, for the binding X 1 M 4 XM

"
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(3)

The change in heat (DQ) measured between the completions of two
consecutive injections is corrected for dilution of the protein and ligand in
the cell according to standard Marquardt method (32,33). The free energy
change (DG) during the interaction was calculated using the relationship:
(DG ¼ DH  TDS ¼ RT ln Ka). All the experiments were performed at
37°C unless otherwise indicated.
The role of electrostatic interactions in the complex formation was evaluated by performing ITC experiments in 50 mM Tris-HCl buffer of various
ionic strengths. The ionic strengths of the buffers were altered by adding
sodium chloride (NaCl) (35–150 mM). To study the role of hydrophobic interactions in the complex formation, experiments were performed in 50 mM
Tris-HCl buffer (pH 7.4) containing various concentrations of glycerol
(125–250 mM).

Size-exclusion chromatography studies
All size-exclusion chromatography (SEC) experiments were carried out at
room temperature on a prepacked Superdex 75 gel ﬁltration column (1.6 3
60 cm) using a ÄKTA Puriﬁer system (Amersham Biosciences, Uppsala,
Sweden). The column was eluted with 50 mM Tris-HCl buffer (pH 7.4) or
the speciﬁed elution buffer, at a ﬂow rate of 1 ml/min. The sample volume
applied to the column was 4 ml. The column was calibrated using ovomucoid (28 kDa) ribonuclease (15.6 kDa), cytochrome C (12 kDa), apoprotinin
(7 kDa), and pelovaterin (4 kDa) (34) as molecular weight markers. The void
volume was determined by running Blue Dextran. The column was equilibrated with at least two bed volumes of the elution buffer before each run.
Electrostatic contributions in the hemextin AB complex formation were
studied by monitoring its elution in 50 mM Tris-HCl buffer (pH 7.4) with
different concentrations of NaCl (75 and 150 mM). Hydrophobic contribu-

tions for the complex formation were determined by recording the elution of
hemextin AB complex in 50 mM Tris-HCl buffer (pH 7.4) with different
concentrations of glycerol (125 and 250 mM). In both the studies, the column was ﬁrst equilibrated with the desired buffer before the application of
the reconstituted hemextin AB complex in the respective buffer to the column. The protein elution was monitored by recording absorbance at 280 nm.

Anticoagulant activity
The anticoagulant activity of individual hemextins and hemextin AB complex were determined using prothrombin time clotting assay (A. J. Quick,
1935). The anticoagulant activity of a speciﬁc concentration of hemextin
A (4.4 mM), hemextin B (4.4 mM), and hemextin AB complex (0.22 mM) was
monitored in 50 mM Tris-HCl (pH 7.4) containing different concentrations
of NaCl (35–150 mM for studying the role of electrostatic interactions) and
glycerol (125–250 mM for studying the role of hydrophobic interactions).
The concentrations of hemextin A and hemextin AB complex were chosen
in a way such that in the absence of salt/glycerol the recorded clotting times
are similar. Control experiments were performed without the addition of the
anticoagulant proteins to evaluate the effect of salt and glycerol on clotting.

One-dimensional NMR spectroscopy
One-dimensional (1D) proton NMR experiments were carried out using
Bruker 700 MHz spectrometer (Billerica, MA), equipped with a modern cryoprobe, and electronic variable temperature unit. The spectra were acquired
using Topspin software (Bruker) interfaced to the spectrometer. Hemextin A
(0.5 mM) and hemextin B (0.5 mM) were prepared in 50 mM Tris-HCl buffer
(pH 7) and transferred to a 5-mm diameter Willmad NMR tube. All deuterated
solvents were purchased from Aldrich Laboratories (Milwaukee, WI) with
99.9% isotopic purity. The spectral width was set to 11,202 Hz for all NMR
experiments. The huge resonance due to the water protons was suppressed by
the WATERGATE pulse sequence (35). Typically, 512 scans were averaged
for each free induction decay before apodization and then performing the
Fourier transformation. 1H chemical shifts were referenced to a sodium 2,2dimethyl-2-silapentane-5-sulfonate solution (DSS).

RESULTS AND DISCUSSION
Conformational changes during the
complex formation
It has been shown previously that hemextin A and hemextin
B interact with each other and form a 1:1 heterotetrameric
complex and this complex formation is important for its
ability to inhibit FVIIa and clot initiation (24). To study the
conformational changes associated with the hemextin AB
complex formation we used far-UV CD. First, we recorded
the CD spectra of individual hemextins A and B (Fig. 1, A
and B). Their CD spectra display negative minima at 217 nm
and positive maxima at 196 nm, which are due to the n to p*
transition and the p to p* transition of the amide chromophore, respectively, typical of a b-sheet structure (Fig. 1, A
and B). Next, a titration CD experiment was performed to
study the complex formation between the two proteins. In this
experiment, the concentration of hemextin A was kept constant at 0.5 mM and the conformational changes in hemextin
A in the presence of various concentrations of hemextin B
were recorded. The shape of the CD spectrum upon addition
of hemextin B to hemextin A did not change signiﬁcantly
Biophysical Journal 93(11) 3963–3976
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Changes in molecular diameters during the
complex formation
The diameter of the individual hemextins and hemextin AB
complex were determined in both gas and solution phases.
In the gas phase analyses using GEMMA, hemextin A, and
hemextin B showed the apparent molecular diameters of
10.20 6 0.38 nm and 8.82 6 0.42 nm, respectively (Fig. 2).
Hemextin AB complex exhibited a larger diameter of 16.30
6 0.43 nm. To further conﬁrm on the GEMMA results, we
examined the effect of toxin C, another three-ﬁnger toxin
isolated from the venom of H. haemachatus, on the molecular
diameters of hemextins A and B, to determine the speciﬁcity
of interaction. Toxin C did not affect the anticoagulant activity of hemextin A in prothrombin time clotting assay (data
not shown) and did not form a complex with hemextin A. At
equimolar concentration of toxin C, the molecular diameter
of hemextin A or hemextin B remains unaffected (Fig. 2).
The solution phase studies with DLS also conﬁrmed the increase in molecular diameter associated with the complex formation. Single scattering populations (unimodal distribution)
for hemextin A, hemextin B, and hemextin AB complex were

FIGURE 1 Conformational changes associated with the formation of
hemextin complex. CD spectra of (A) hemextin A (0.5 mM) and (B) hemextin
B (0.5 mM). (C) Conformational changes in hemextin A with increasing
concentrations of hemextin B: (black) hemextin A 0.5 mM; (red) hemextin A
0.5 mM plus hemextin B 0.25 mM; (green) hemextin A 0.5 mM plus
hemextin B 0.4 mM; (blue) hemextin A 0.5 mM plus hemextin B 0.5 mM;
(gray) hemextin A 0.5 mM plus hemextin B 0.9 mM; (inset) the observed
change in the CD spectra around the 217-nm region.

(Fig. 1 C). However, the CD intensity at 217 nm increases
with the incremental addition of hemextin B and reaches maximum at the 1:1 molar ratio suggesting increase in b-sheet
content and stoichiometric binding of hemextin B to hemextin
A, respectively (see Supplementary Material, Fig. S1A). The
difference spectrum obtained by subtracting the CD spectrum
of 1:1 complex from the sum of the CD spectra of hemextin A
and hemextin B indicates the conservation of b-sheet structure in the complex, suggesting possible folding upon complex formation. (see Supplementary Material, Fig. S1B).
Biophysical Journal 93(11) 3963–3976

FIGURE 2 Measurement of molecular diameter during the hemextin AB
complex formation using GEMMA. The molecular diameters of the individual hemextins and the hemextin AB complex are calculated based on
their electrophoretic mobility. The formation of hemextin AB complex leads
to an increase in the molecular diameter. Addition of equimolar toxin C does
not show any signiﬁcant increase in the molecular diameters of hemextin A
and hemextin B validating the obtained data.
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observed in DLS suggesting the homogeneity of the sample
preparations with hydrodynamic diameters of 10.3, 9.9, and
16.8 nm, respectively (Fig. 3 A). The narrow size distribution
of a single monodisperse species for 1:1 mixture of hemextin
A and hemextin B suggests the formation of a well-deﬁned
complex. It is important to note that the tetrameric hemextin
AB complex and individual hemextins exhibited comparable
molecular diameters in both gas and solution phases. The apparent molecular dimensions are signiﬁcantly larger than the
theoretical diameter estimated for a native protein and much
smaller than the estimated length of the proteins in completely
‘‘extended conformation’’ (36,37). Such an anomaly could
be due to the nonglobular conformation of the proteins (38).
The molecular diameter of hemextin AB complex is, however, much smaller compared to the estimated size of a tetramer
indicating that the four monomers are compactly packed.

Thermodynamics of the hemextin AB
complex formation
ITC permits the study of macromolecular interactions in solution and is the only technique that can resolve the enthalpic
and entropic components of binding afﬁnity (39–41). It was
used to study the thermodynamics of hemextin AB complex
formation. Each injection gave rise to negative (exothermic)
heat of reaction (Fig. 4). The binding isotherm ﬁts to a single
set of binding sites model, suggesting an equimolar binding
between hemextin A and hemextin B. The interaction between them is thermodynamically allowed (as indicated by
negative DG) (Table 1). A favorable negative DH but unfavorable negative DS changes indicate that the complex
formation is enthalpically driven, and van der Waals interactions and hydrogen bonds may play an important role in the
complex formation (42). Also, the formation of a less dynamic complex is entropically disfavored, as has been observed in the studies pertaining to the dimerization of insulin
(43). Thus the recorded negative entropic change (DS) indicates
the formation of a less ﬂexible or less disordered hemextin
AB complex. The binding constant (KA) for the formation
of hemextin AB complex was 2.23 3 106 M1 and it falls
within the KA values for protein-protein interactions in biologically relevant processes that range from 104 to 1016 M1
(44).

The effect of temperature on the hemextin AB
complex formation
To further understand energetics of the complex formation,
complete temperature proﬁle of the thermodynamic parameters associated with the binding of hemextin A to hemextin
B was studied over the temperature range of 25–45°C. The
temperature dependence of DH is shown in Fig. 5 A and
Table 1. The temperature dependence of DH over a narrow
temperature range is given by the equation:

3967

DH ¼ DH0 1 DCp ðT  T0 Þ;

(4)

where, DH0 is the binding enthalpy at an arbitrary reference
temperature and DCp is the heat capacity change of binding.
The DCp obtained from the slope (DCp ¼ dDH / dT) (Fig. 5 A)
is 163 cal/K1mol1. Negative DCp indicates a reduction
in the nonpolar solvent-accessible surface area, as explained
by the following equation (45,46),
DCp ¼ 0:45ðDASAnonpol Þ  0:26ðDASApol Þ cal=molK; (5)
where, DASApol and DASAnonpol are the change in the polarand nonpolar-accessible surface areas, respectively. Thus,
hemextin AB complex formation is associated with the
burial of hydrophobic surface area.
Fig. 5 B shows the plot of DG and DH as a function of
TDS. It is clear that the DG of binding remained temperature
independent and is a result of linear dependence of DH on
TDS. This strongly suggests the enthalpy-entropy compensation for the binding of hemextin A to hemextin B. This
phenomenon is a universal feature for protein-peptide interactions, where weak molecular interactions undergo constant
rearrangements to realize a lower free energy of binding
(42,47–49). The correlation between entropy and enthalpy
for a range of interacting protein-protein systems was determined (r2 ¼ 0.956). The data for hemextin AB complex fall
well along this correlation line (see Supplementary Material,
Fig. S2).
The negative DCp indicates the net thermodynamic driving
force for the association to shift from entropic to enthaplic
with increasing temperature. At the intersection point of both
lines DG ¼ DH ¼ 8.4 kcal mol1 (Fig. 5 B), which corresponds to a temperature Ts (temperature at which the contribution from entropy is zero (50,51)). At Ts the contribution
from entropy changes from favorable to unfavorable. From
Fig. 5 A, DH ¼ 8.4 kcal mol1 is connected with a Ts of
16°C (289 °K).
The negative DCp for the hemextin AB complex formation
further suggests that the observed entropy change upon binding must include signiﬁcant contribution from the hydrophobic effect in the physiological temperature range. Therefore,
for protein-protein/ligand interaction(s) the net entropy of association is given by the equation:
DSassoc ¼ DSHE 1 DSrt 1 DSother ;

(6)

where, DSHE, DSrt, and DSother are the entropy changes due to
hydrophobic effect, reduction of rotational and translational
degree of freedom, and from other sources, respectively.
At Ts, the overall entropy of association is zero and the
above equation becomes:
DSassoc ¼ DSHE ðTs Þ 1 DSrt 1 DSother ¼ 0:

(7)

In the absence of crystallographic data, the DSHE(Ts) was
estimated from the equation,
DSHE ðTs Þ ¼ 1:35DCp lnðTs =386Þ;

(8)
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FIGURE 3 Determination of hydrodynamic diameter using DLS. (A) CONTIN analysis hemextin A, hemextin B, and hemextin AB complex in 50 mM TrisHCl buffer. Effect of various concentrations of NaCl (B) and glycerol (C) on hemextin AB complex. The calculated hydrodynamic diameters for each
molecular species are shown. (Note the dimer formed in glycerol has a different diameter than the one formed in salt.)
Biophysical Journal 93(11) 3963–3976
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entropy term, the analysis of coupled folding is typically not
suitable for distinguishing small extents of folding from the
rigid body case. However, from the nonzero value of DSother
it can be concluded that that there is no evidence for largescale coupled folding, during the formation of hemextin AB
complex. Again, C ¼ DSother / 5.6 cal deg1 mol1, where
C designates the number amino acid residues involved in the
folding transition (54). Therefore, approximately three residues are involved in the folding transition. Also, from Fig. 5
B the enthalpic counterpart of TS, namely TH, the temperature
at which the enthalpic contribution to the Gibbs free energy
of binding changes from favorable to unfavorable is calculated to be 244 °K. Therefore, below 29°C the binding
process is entropically driven and only in the interval between TS and TH (i.e., between 29°C and 16°C), both the entropic and enthalpic parts of the Gibbs free energy of binding
are favorable.

Oligomerization states of the anticoagulant
complex and individual hemextins

FIGURE 4 Interaction studies between hemextin A and B using ITC. (A)
Raw ITC data showing heat release upon injections of 1 M hemextin B into a
1.4-ml cell containing 0.1 mM of hemextin A; (B) integration of the raw ITC
data yields the heat/mol versus molar ratio. The best values of the ﬁtting
parameters are 1.04 for N, 2.23 3 106 M1 for KA, and 11.68 kcal M1 for
DH (Table 1).

and found to be 64 cal deg1 mol1. It has been shown that
protein-protein interaction DSrt is nearly equal to 50 cal
deg1 mol1 (52,53). Thus the DSother is calculated to be
14 cal deg1 mol1. Because of experimental uncertainties
in the heat capacity change and the entropy of complex formation, as well as in the value of the rotational-translational

Hemextin AB complex exists as a tetramer and the complex
formation is pivotal for its potent anticoagulant activity. In
addition, as determined in prothrombin time and kinetic assays the stoichiometry of complex formation is 1:1 (24,25).
We evaluated the role of both electrostatic and hydrophobic
interactions in complex formation.
Electrostatic interactions in hemextin AB complex formation

Firstly, the binding constant for hemextin AB complex
formation was determined by ITC in buffers of increasing
ionic strength. The log KA values for the complex formation
decreased linearly with the increasing NaCl concentration
(Fig. 6 A, Table 1), illustrating the participation of electrostatic interactions in complex formation. Secondly, the effect
of buffer ionic strength on the assembly of hemextin AB

TABLE 1 Thermodynamic analysis of hemextin A-hemextin B interaction
KA 3 106 (M1)

DH (kcal/mol)

DS (cal/deg mol)

DG (kcal/mol)

At different temperatures (°C)
25
37
45

2.07
2.23
1.97

9.92
11.7
13.12

4.43
8.645
12.49

8.6
9
9.15

At different salt concentrations
35 mM NaCl
75 mM NaCl
100 mM NaCl
150 mM NaCl

0.63
0.33
0.02
0.002

10.5
9.32
7.31
5.01

7.2
4.8
3.82
1.2

8.2
7.8
6.12
4.6

At different glycerol concentrations
125 mM Glycerol
175 mM Glycerol
250 mM Glycerol

0.32
0.2
0.05

10.8
10.5
9.4

11.01
10.6
10

7.6
7.2
6.4

ITC experiments

All ITC experiments in salt and glycerol were carried out at 37°C.
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FIGURE 6 Hemextin AB complex formation under different buffer conditions. (A) Dependence of KA on the ionic strength of the buffer. The binding
afﬁnity decreases with the increase in buffer ionic strength indicating the
importance of electrostatic interactions. (B) Dependence of KA on the glycerol concentration. The binding afﬁnity decreases with the increase in glycerol concentration indicating the importance of hydrophobic interactions.

FIGURE 5 Thermodynamics of hemextin A-hemextin B interaction. (A)
Effect of temperature on the energetics of hemextin A-hemextin B interaction: enthalpy change (DH), change in entropy term (TDS), and free energy
change (DG). (B) Enthalpy-entropy compensation in complex formation.
(Point of intersection of lines corresponding to DH and DG corresponds to Ts)

complex was examined with the help of SEC. In the absence
of salt, the complex eluted as a tetramer and the individual
hemextins as monomers (Fig. 7 A). In the presence of 75 mM
NaCl the tetramer started dissociating into dimer (Fig. 7 B).
With further increase in ionic strength of the buffer (NaCl
150 mM) the complex eluted mostly as a dimer and monomer(s). ESI-MS and HPLC analyses of the dimer peak indicated that it contains both hemextins A and B (data not
shown). This observation again reconﬁrms the importance of
electrostatic interactions in hemextin AB assembly. Interestingly, an additional protein peak eluted slower than the
monomers indicating hemextin A and/or hemextin B was
undergoing a conformational change in buffers of high ionic
strength. Therefore, we monitored the elution proﬁles of individual hemextins in buffers of high ionic strength. Hemextin
A at 75 mM NaCl concentration showed two peaks; a second
Biophysical Journal 93(11) 3963–3976

protein peak eluted slower than the monomer (Fig. 7 B).
With further increase in the ionic strength (NaCl 150 mM)
hemextin A eluted mostly in the second peak. ESI-MS and
HPLC analyses of this second peak show that it is structurally intact hemextin A (data not shown). Thus, the change
in the elution proﬁle of hemextin A in buffers of higher ionic
strength hinted a conformational change in the protein, which
was further conﬁrmed by 1D NMR studies (see below). Increased ionic strength of buffer did not have any effect on the
elution of hemextin B (Fig. 7, A and B).
We also determined the hydrodynamic diameters of hemextin
AB complex and individual hemextins in buffer solutions of
high ionic strength using DLS (Fig. 3 B). (As GEMMA works
on the principle of nano-ESI, we did not determine the molecular diameters in buffers containing high salt using this
technique.). At high salt concentrations, the hemextin AB
complex exhibits a high polydispersity indicating the presence of different species. At 75 mM NaCl, there are three
different populations. In addition to the monomer(s) and the
tetramer, there is an additional population with an apparent
molecular diameter of 12.4 nm. Based on our SEC results
(Fig. 7 B), we suggest that the 12.4-nm species could be the
dimeric hemextin AB complex. As expected, the population
of 12.4-nm species increases when the concentration of NaCl
is increased to 150 mM (Fig. 3 B). Thus DLS data also suggest the dissociation of the tetrameric complex to a dimer. As
expected, polydispersity was also observed with hemextin A
in buffers of high ionic strength (Fig. 3 B). An additional population of 11.57-nm-sized particle, in addition to its native
size of 10.4 nm is observed. Based on the SEC (Fig. 7 B) and
1D-NMR (see below), we suggest that the 11.57-nm species
represents the conformationally altered form of hemextin A.
No change in the hydrodynamic diameter of hemextin B was
observed with the increase in buffer ionic strength (Fig. 3 B).
To understand the implications of the change in conformation of hemextin A and the breakdown of tetrameric complex,
we monitored the anticoagulant activity of the complex and
individual hemextins in buffers of high ionic strengths. Higher
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FIGURE 7 SEC studies of hemextin AB complex in different buffer conditions. (A) Elution proﬁles of hemextin AB complex in Tris-HCl buffer. Effect of
various concentrations of NaCl (B) and glycerol (C) on hemextin AB complex. The tetrameric complex (peak denoted by 4) dissociates into dimer and
monomer (peaks denoted by 2 and 1, respectively) with the increase in salt or glycerol. Asterisk denotes the peak containing conformationally altered hemextin
A. (D) Calibration of the column using the following proteins as molecular weight markers: ovomucoid (28 kDa), ribonuclease (15.6 kDa), cytochrome C (12
kDa), apoprotinin (7 kDa), and pelovaterin (4 kDa). The molecular weights of the tetramer, dimer, and monomers were calculated from the calibration curve.

concentration of NaCl did not affect the anticoagulant activity of hemextin A (Fig. 8 A). Thus despite the change(s) in
conformation (see below), hemextin A retains its anticoagulant activity. The anticoagulant activity of hemextin AB complex, in contrast, decreased with the increase in ionic strength
up to 100 mM NaCl (Fig. 8 A). However, further increase in
the salt concentration did not signiﬁcantly affect the anticoagulant activity. At 150 mM NaCl the complex exists as a

mixture of a dimer, monomer(s), and conformationally altered hemextin A as is evident from the SEC experiments
(Fig. 7 B). Therefore, the remaining anticoagulant activity
observed at 150 mM or higher NaCl concentration is due to
the presence of monomeric hemextin A and not due to dimeric hemextin AB complex. Hence, it can be concluded that
the dimer formed at high salt concentrations does not have
any signiﬁcant anticoagulant activity.

FIGURE 8 Effect of buffer conditions on anticoagulant activity. Effect of various concentrations of NaCl
(A) and glycerol (B) on the anticoagulant activity of
hemextin A (O), hemextin B (M), hemextin AB
complex (:). The anticoagulant activity of hemextin
AB complex decreases with the increase in concentrations of NaCl and glycerol. The arrows indicate the
concentrations of (A) NaCl and (B) glycerol where the
anticoagulant complex exists mostly as a mixture of
dimer and monomers (see text for details); (n) denotes
the anticoagulant activity recorded in the absence of the
proteins.
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Thus, these studies in buffers of high ionic strength
strongly suggest that electrostatic interactions play crucial
role in the assembly of hemextin AB complex. As hemextin
A undergoes conformational change(s) in the presence of salt
(see below), the dissociation of tetramer in a buffer of high
ionic strength may not only be due to the disruption electrostatic interaction but also due to conformational change(s)
in hemextin A. Further, high salt concentration leads to the
formation of a dimer that is functionally inert (in terms of
lack of synergic increase in anticoagulant activity). Based on
the obtained results, we hypothesize that the dimer assembled at 150 mM NaCl concentration is probably formed by
the interplay of predominantly hydrophobic interactions. Therefore, successive experiments were carried out to evaluate the
importance of hydrophobic interactions in the complex formation.
Hydrophobic interactions in the hemextin AB
complex formation

We carried out ITC experiments in buffers containing increasing concentrations of glycerol. Adsorption of glycerol
to hydrophobic patches on the surface of proteins interferes
in the hydrophobic interactions (55,56). A decrease in the
association constant was observed with the increase in glycerol concentration (Fig. 6 B and Table 1), showing the importance of hydrophobic interactions in the complex formation.
We monitored the elution of hemextin AB complex in buffers
containing glycerol on a Superdex 75 column (Fig. 7 C). In
buffers containing high glycerol concentration the tetramer
dissociates into dimer and monomers. ESI-MS and HPLC
analyses of the dimer peak indicate that it contains both
hemextins A and B (data not shown). However, no additional
peak corresponding to altered conformation of hemextin A
was observed. The elution of individual hemextins remained
unaltered in the presence of glycerol (Fig. 7 C). The breakdown of hemextin AB complex in the presence of glycerol
was also observed in the DLS studies (Fig. 3 C). At 125 mM
glycerol concentration, an additional population of 12.8-nmsized species was observed in addition to the monomers and
the tetrameric complex. Based on SEC studies, we propose
that the 12.8-nm species is a dimer. The 12.8-nm species increases with the increase in glycerol concentration (Fig. 3 C).
It is important to note that the apparent molecular diameter of
this dimer is different from the dimer formed in buffers of
high ionic strength (12.8 vs. 12.4 nm; Fig. 3, B and C). (As
GEMMA works on the principle of nano-ESI, we did not
determine the molecular diameters in buffers containing glycerol using this technique.). No polydispersity was observed
in the case of individual hemextins in the presence of glycerol (Fig. 3 C).
To further understand the implication of the breakdown of
hemextin AB complex in glycerol, we monitored its anticoagulant activity and that of the individual hemextins in buffers
containing different concentrations of glycerol. The anticoBiophysical Journal 93(11) 3963–3976
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agulant activity of hemextin AB complex decreased with the
increase in glycerol concentration (Fig. 8 B). At 125 mM
glycerol concentration there is no decrease in the anticoagulant activity. However, at 250 mM glycerol concentration
(at which hemextin AB complex exists as a mixture of dimer
and monomers; Fig. 7 C) there is a decrease in the anticoagulant activity. But this activity is higher than that of the
anticoagulant effect of hemextin A alone. Therefore, we conclude that the dimer observed at 250 mM glycerol concentration exhibits the anticoagulant activity higher than hemextin
A alone but lower than that of the tetramer. In other words,
dimer formed in the presence of glycerol is different from the
dimer formed in salt; the former dimer exhibiting an increased
anticoagulant activity compared to hemextin A alone, whereas
the latter not doing so. Glycerol, however, did not affect the
anticoagulant activity of individual hemextins (Fig. 8 B).
The dissociation of the tetramer into dimer and monomers
in the presence of glycerol indicates the importance of hydrophobic interactions in the tetrameric complex formation.
This role of hydrophic interaction is further supported by the
negative DCp change observed during the formation of
hemextin AB complex.
Our data strongly suggest that both electrostatic and hydrophobic interactions are important for the formation of tetrameric hemextin AB complex. To conﬁrm that decrease in
binding afﬁnity between the monomers observed in salt and
glycerol is not a solute osmotic effect, the KA recorded in salt
and glycerol was plotted against osmotic pressure (see Supplementary Material, Fig. S3). At similar osmolality of salt
and glycerol decrease in binding afﬁnity was more pronounced in salt than glycerol. This indicates that fall binding
afﬁnity is due to disruption of either electrostatic (for salt) or
hydrophobic (for glycerol) interactions.
The effect of buffer conditions on the
conformation of hemextins
Earlier studies using SEC (Fig. 7 B) and DLS (Fig. 3) indicated that hemextin A undergoes conformational changes
in the presence of salt. We conducted 1D-NMR analysis to
study the conformation of hemextins A and B under different
buffer conditions (Fig. 9). In the presence of NaCl, there is a
decrease in the number of Ha resonance peaks between 4.8
and 6 ppm in the case of hemextin A (Fig. 9 A). These chemical shifts contribute to the interresidue NOE crosspeaks
between Ha of different amino acid residues forming antiparallel b-sheet structure typically observed in all three-ﬁnger
toxins (57). Thus a decrease in the b-sheet content of hemextin
A is observed in the presence of NaCl. In addition, there are
several changes in the chemical shifts of side chains. A notable change is a highly shielded methyl peak that appears at
the negative chemical shift value (0.38 ppm) in the presence of salt. These observations strongly support conformational
changes in hemextin A in the presence of NaCl. The overall
dispersion of 1D proton NMR spectra of hemextin A in the
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FIGURE 9 One-dimensional 1H NMR
studies. Spectrum of (A) hemextin A and
hemextin B under different buffer conditions. Note that in the presence of salt,
hemextin A undergoes a conformational change; also, the peaks are sharp
throughout the spectrum. In addition, all
1D 1H NMR spectra also exhibited a
wide range of chemical shift dispersions
(amide region 7–10 ppm, Ha region
3.8–6 ppm, and methyl region 0.4 –to
1.5 ppm), which is a characteristic of
well-folded proteins. Therefore, the observed structural change is not due to
resonance broadening or aggregation
(because no aggregation state was observed as mentioned) but it is only due to
addition of NaCl to hemextin A.

presence of glycerol (deuterated) remains the same with the
subtle changes in the amide region (Fig. 9 A). Thus, hemextin
A did not undergo any signiﬁcant conformational change
upon the addition of glycerol. Similar studies with hemextin
B show that it did not undergo any signiﬁcant conformational changes in the presence of NaCl or glycerol (Fig. 9 B)
since there is almost one to one match for the spectral frequencies.
Model for hemextin AB complex
Based on our studies we propose a model for the assembly
of hemextin AB complex (Fig. 10). Two molecules each of
hemextin A and B form the tetrameric complex in Tris-HCl
buffer (Fig. 10 A). The formation of this compact, synergistic
complex is important for its anticoagulant activity. As illustrated earlier, hemextin AB dimer in high salt is different
from the dimer formed in the presence of glycerol (Fig. 10 C).
The former dimer has an apparent molecular diameter of
12.4 nm and lacks anticoagulant activity, whereas the latter
has an apparent molecular diameter of 12.8 nm and exhibits
slightly higher anticoagulant effects (Fig. 10 C). Thus, the
breakdown of tetramer to dimer probably occurs in two
different interfaces of interaction between hemextin A and B.
One interface is sensitive to the ionic strength of its surroundings whereas the other is sensitive to glycerol (Fig. 10 C).
Further, in the presence of salt, hemextin A undergoes conformational changes (Fig. 10 B) which may interfere in the

tetramer formation. The dimer formed under high ionic conditions lacks the complete synergistic anticoagulant site (marked
by a dotted semicircle in Fig. 10 C) and hence the resultant
dimer is as active as hemextin A alone. (Fig. 8). In contrast,
hydrophobic interactions are predominant in the second interface. Therefore, glycerol dissociates the tetramer into dimers.
However, in this case only minor changes occur in the synergistic anticoagulant site of the complex (as shown in
Fig. 10 C) and hence the resultant dimer is active (Fig. 8).
We propose that the tetramer formation most likely stabilizes
the anticoagulant site of hemextin A. The binding between
hemextin AB complex/hemextin A and FVIIa has been
characterized to validate the proposed model (Y. Banerjee,
J. Mizuguchi, E. Person, R. Doley, S. Iwanaga, and R.
Manjunatha Kini, unpublished data).
CONCLUSION
Hemextin AB complex is the ﬁrst synergistic anticoagulant
complex isolated from snake venom comprising solely two
three-ﬁnger toxins—hemextin A and hemextin B (24). The
tetrameric complex formation is a prerequisite for the synergistic inhibition of FVIIa. This complex formation is an
enthalpically driven process. The complex exhibits identical
apparent molecular diameters in gas and solution phases. Thermodynamics of hemextin AB complex formation indicates
the absence of large-scale coupled folding. Both electrostatic
and hydrophobic interactions are important for the assembly
Biophysical Journal 93(11) 3963–3976
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FIGURE 10 A proposed model of hemextin AB complex. (A) Schematic diagram depicting the formation of
hemextin AB complex. Hemextins A and B, two structurally similar three-ﬁnger toxins, form a compact and rigid
tetrameric complex with 1:1 stoichiometry (24). (B) Schematic diagram showing the effect of salt and glycerol on
conformations of hemextins A and B. Hemextin A undergoes a conformational change in the presence of salt.
(C) Dissociation of the tetrameric hemextin AB complex in
the presence of salt and glycerol. The dissociation probably
occurs in two different planes. Thus the hemextin AB
dimer in high salt is different from the dimer formed in the
presence of glycerol. Two putative anticoagulant sites are
shown with dotted semicircles (see text for details).

of the tetramer. Based on our results we propose that the tetramer formation takes place by the participation of two interfaces. One of the interfaces is predominantly sensitive to
the buffer ionic strength, indicating that electrostatic interactions are predominantly active in that interface. The other
being sensitive to glycerol concentration of the solution indicates the participation of mostly hydrophobic interactions.
The proposed model may help in a better understanding of
the structure-function relationship of this novel anticoagulant
complex.
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